Blood supply to the caudate lobe of the liver from the right inferior phrenic artery: observation by cone-beam computed tomography during arteriography

Miyayama, Shiro; Yamashiro, Masashi; Sugimori, Natsuki; Ikeda, Rie; Ishida, Takuya; Sakuragawa, Naoko

doi:10.1007/s00261-020-02489-4

Cited by 6 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 36 , 37 Herein, we proposed a novel treatment approach, TACE plus ISI, wherein 125 I seeds have a long half-life and can irradiate the dividing tumor cells at close range (< 1 c m). The irradiation is not affected by “heat sink effect” and reduces the formation of new collateral blood supply to the HCC-CL caused by initial or repeated TACEs, such as the right inferior phrenic artery, 38 thereby achieving effective local control of the tumors.…”

Section: Discussionmentioning

confidence: 99%

Caudate Lobe Hepatocellular Carcinoma Treated with Sequential Transarterial Chemoembolization and Iodine 125 Seeds Implantation: A Single-Center Retrospective Study

Liu

Chen

Qian

et al. 2021

CMAR

View full text Add to dashboard Cite

Resection of the hepatocellular carcinoma (HCC) in the caudate lobe (CL) is challenging even for accomplished surgeons. This retrospective study evaluated the safety and efficacy of transarterial chemoembolization (TACE) and iodine 125 seeds implantation (ISI) for unresectable or "ablation unsuitable" HCC-CL detected at the initial presentation in clinical practice. Patients and Methods: A total of 20 HCC-CL patients undergoing sequential TACE and ISI from January 2014 to October 2018 were enrolled in this study. The overall survival (OS), progression-free survival (PFS), tumor response rate, and complication rates were analyzed and compared to non-caudate lobe (NCL) HCC patients. Multivariate analyses for potential clinical and radiological factors were performed using the Cox proportional hazard model. Results: The technical success rate was 100%, as all the patients received 28 ISI treatments. The median OS was 35 months. The 1-, 3-, and 5-year OS rates were 100%, 63.2%, and 11.1%, respectively. The median PFS was 16 months. The objective response rate was 60.0%. The puncture tract bleeding (2/20) and pneumothorax (1/20) were the most common complications in operation, but no operation-related deaths occurred. One year after the surgery, biliary tract injury occurred in 1 patient, necessitating percutaneous biliary intervention. No statistical difference was observed between the CL and NCL groups. Multivariable analysis revealed that Barcelona Clinic Liver Cancer stage B and tumor size >3 cm were two significant factors associated with OS. Conclusion: Sequential TACE and ISI were associated with the survival benefits in HCC-CL and should be considered as a reliable therapy for surgeons and interventional radiologists.

show abstract

Section: Discussionmentioning

confidence: 99%

Caudate Lobe Hepatocellular Carcinoma Treated with Sequential Transarterial Chemoembolization and Iodine 125 Seeds Implantation: A Single-Center Retrospective Study

Liu

Chen

Qian

et al. 2021

CMAR

View full text Add to dashboard Cite

show abstract

“… 2 , 8 In theory, multiple repeat embolizations may reduce tumor recurrence, but the arteries supplying the HCC in the caudate lobe that recurs after endovascular intervention are frequently altered during subsequent chemoembolization therapy, 11 making repeat chemoembolization difficult. The caudate arteries can initially originate from the extrahepatic arteries, 12 and the right inferior phrenic artery (RIPA) is the most common extrahepatic artery. 12 , 13 , 14 Other less common vessels supplying recurrent tumors include the right gastric artery, the left gastric artery, the pancreatic artery and the adrenal artery.…”

Section: Transcatheter Arterial Chemoembolizationmentioning

confidence: 99%

“…The caudate arteries can initially originate from the extrahepatic arteries, 12 and the right inferior phrenic artery (RIPA) is the most common extrahepatic artery. 12 , 13 , 14 Other less common vessels supplying recurrent tumors include the right gastric artery, the left gastric artery, the pancreatic artery and the adrenal artery. 5 , 7 , 11 The possibility of extrahepatic arterial supply, such as the RIPA, should therefore not be overlooked during hepatic arteriography.…”

Section: Transcatheter Arterial Chemoembolizationmentioning

confidence: 99%

Advances in the interventional therapy of hepatocellular carcinoma originating from the caudate lobe

2022

Journal of Interventional Medicine

View full text Add to dashboard Cite

“…Surgical resection and percutaneous radiofrequency ablation (RFA) can be used as a curative treatment for HCC-CL (11,12). However, resection of the HCC-CL is a challenging task for accomplished surgeons owing to the tumor's deep location that is adjacent to the inferior vena cava and hepatic vein and narrow surgical margin (2,3,6,13,14). Radiofrequency therapy cannot be performed safely under certain circumstances, such as thermal injury of adjacent structure, heat sink effect (near major vessels), and limited tumor necrosis range (15).…”

Section: Introductionmentioning

confidence: 99%

“…Baseline clinical characteristics of patients.such as localized progression or metastasis in the liver. The average number of TACE sessions was 5(1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15). The median follow-up period was 17.5 months (range, 1-65 months).…”

mentioning

confidence: 99%

Superselective Transarterial Chemoembolization for Unresectable or “Ablation Unsuitable” Hepatocellular Carcinoma in the Caudate Lobe: A Real World, Single-Center Retrospective Study

et al. 2021

View full text Add to dashboard Cite

ObjectivesTo analyze the clinical outcomes of Transarterial chemoembolization (TACE) for unresectable or “ablation unsuitable” hepatocellular carcinoma (HCC) in the caudate lobe (CL) found at initial presentation in clinical practice.MethodsFifty-eight patients with HCC-CL undergoing conventional TACE from January 2015 to January 2020 were enrolled in our medical center. Overall survival (OS), progression-free survival (PFS), tumor response rate and major complication rates were analyzed. Multivariate analyses for potential clinical and radiologic factors were performed by using the Cox proportional hazard model.ResultsThe median OS was 23 months (95%CI: 18.1-27.9), and the median PFS was 11 months (95%CI: 7.4-14.6). The 1-, 3-, and 5-years OS rates were 66.5%, 31.9% and 15.7%, respectively. The 0.5, 1-, and 3-years PFS rates were 60.3%, 44.5% and 6.3%, respectively. Objective response rate was 53.4% and disease control rate was 79.3%. The most serious complication was bile duct injury, with an incidence of 3.4%. Multivariable analysis revealed that total bilirubin, Barcelona Clinic Liver Cancer stage, nonselective chemoembolization and TACE session were four significant factors associated with OS.ConclusionsSuperselective TACE treatment might be associated with better survival benefits in unresectable or “ablation unsuitable” HCC in the CL without macroscopic vascular invasion (MVI) and adequate liver function, compared with the non-selective TACE group, and should be considered as an important reliable therapy for surgeons and interventional radiologists.

show abstract

Blood supply to the caudate lobe of the liver from the right inferior phrenic artery: observation by cone-beam computed tomography during arteriography

Cited by 6 publications

References 22 publications

Caudate Lobe Hepatocellular Carcinoma Treated with Sequential Transarterial Chemoembolization and Iodine 125 Seeds Implantation: A Single-Center Retrospective Study

Caudate Lobe Hepatocellular Carcinoma Treated with Sequential Transarterial Chemoembolization and Iodine 125 Seeds Implantation: A Single-Center Retrospective Study

Advances in the interventional therapy of hepatocellular carcinoma originating from the caudate lobe

Superselective Transarterial Chemoembolization for Unresectable or “Ablation Unsuitable” Hepatocellular Carcinoma in the Caudate Lobe: A Real World, Single-Center Retrospective Study

Contact Info

Product

Resources

About